Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas

Metastatic pheochromocytomas and paragangliomas (MPPGs) are rare endocrine malignancies that are associated with high rates of morbidity and mortality because of their large tumor burden and location, progression, and release of catecholamines. Systemic therapies for MPPGs are limited. MPPGs are characterized by pseudohypoxia that may prevent immune system recognition. We conducted a phase II clinical trial of pembrolizumab in patients with progressive MPPGs. The primary endpoint was the non-progression rate at 27 weeks. The secondary endpoints included the objective response and clinical benefit rates, progression free and overall survival duration, and safety. We also determined whether PDL-1 expression and the presence of infiltrating mononuclear inflammatory cells in the primary tumor were associated with clinical response and hereditary background. Eleven patients were included in this trial, four (36%) with germline mutations and seven (64%) with hormonally active tumors. Four patients (40%, 95% confidence interval (CI) 12–74%) achieved the primary endpoint. The objective response rate was 9% (95% CI: 0–41%). The clinical benefit rate was 73% (95% CI: 39–94%). Four patients had grade 3 adverse events related to pembrolizumab. No patients experienced grade 4 or 5 adverse events or a catecholamine crisis. Progression free survival time was 5.7 months (95% CI: 4.37—not reached). The median survival duration was 19 months (95% CI: 9.9—not reached). PDL-1 expression and the presence of infiltrating mononuclear inflammatory cells in the primary tumor did not seem to be associated with disease response. Single-agent pembrolizumab has modest treatment efficacy in patients with progressive MPPGs. Positive responses seemed to be independent of patients’ hereditary backgrounds, tumor hormonal status, and the presence of infiltrating mononuclear inflammatory cells or PDL-1 expression in the primary tumor.

[1]  P. Dahia,et al.  HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: Metastatic pheochromocytomas and paragangliomas: proceedings of the MEN2019 workshop , 2020, Endocrine-Related Cancer.

[2]  C. Jimenez,et al.  Antiangiogenic therapies for pheochromocytoma and paraganglioma. , 2020, Endocrine-related cancer.

[3]  R. Wendt,et al.  High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. , 2020, Current opinion in endocrinology, diabetes, and obesity.

[4]  R. Simon,et al.  Phase 2 study of pembrolizumab in patients with advanced rare cancers , 2020, Journal for ImmunoTherapy of Cancer.

[5]  C. Jimenez,et al.  Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. , 2020, Best practice & research. Clinical endocrinology & metabolism.

[6]  P. Dahia,et al.  Metastatic pheochromocytoma and paraganglioma: proceedings of the MEN2019 workshop. , 2020, Endocrine-related cancer.

[7]  A. Dimberg,et al.  Tumor angiogenesis: causes, consequences, challenges and opportunities , 2019, Cellular and Molecular Life Sciences.

[8]  V. Patel,et al.  The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors , 2019, Journal of Immunotherapy for Cancer.

[9]  W. Erwin,et al.  Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine , 2019, Cancers.

[10]  S. Asa,et al.  A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial , 2019, British Journal of Cancer.

[11]  B. Khoo,et al.  Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Phaeochromocytoma and Paraganglioma , 2019, Neuroendocrinology.

[12]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[13]  N. Stambler,et al.  Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma , 2018, The Journal of Nuclear Medicine.

[14]  C. Jimenez Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer , 2018, Front. Endocrinol..

[15]  B. Helmink,et al.  The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.

[16]  M. Sawyer,et al.  Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Le Chatelier,et al.  Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients , 2018, Science.

[18]  D. Schroeder,et al.  Perioperative outcomes of syndromic paraganglioma and pheochromocytoma resection in patients with von Hippel‐Lindau disease, multiple endocrine neoplasia type 2, or neurofibromatosis type 1 , 2017, Surgery.

[19]  W. Young,et al.  Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years , 2017, The Journal of clinical endocrinology and metabolism.

[20]  R. Dina,et al.  Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior , 2017, Oncoimmunology.

[21]  V. Suman,et al.  Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma , 2017, Endocrine.

[22]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[23]  A. Lam Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours , 2017, Endocrine Pathology.

[24]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[25]  Shouhao Zhou,et al.  Constipation: an overlooked, unmanaged symptom of patients with pheochromocytoma and sympathetic paraganglioma. , 2015, European journal of endocrinology.

[26]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[27]  R. Baum,et al.  Peptide receptor radionuclide therapy with 90Y/177Lu-labelled peptides for inoperable head and neck paragangliomas (glomus tumours) , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  O. Dekkers,et al.  Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta‐analysis , 2014, Clinical endocrinology.

[29]  P. Dahia Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity , 2014, Nature Reviews Cancer.

[30]  A. Tabarin,et al.  One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.

[31]  E. Baudin,et al.  Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma , 2013, Current Oncology Reports.

[32]  M. Hofmann,et al.  Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma. , 2013, The Journal of clinical endocrinology and metabolism.

[33]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[34]  Shreyaskumar R Patel,et al.  Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas , 2012, Cancer.

[35]  Lei Feng,et al.  Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.

[36]  R. Hawkins,et al.  Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  F. Forrer,et al.  Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. , 2008, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[38]  E. Krenning,et al.  Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Sandro Santagata,et al.  A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas , 2005, PLoS genetics.

[40]  P. Vaupel,et al.  Hypoxia-/HIF-1α-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression. , 2018, Advances in experimental medicine and biology.

[41]  Andrew L. Kung,et al.  A HIF1-alpha Regulatory Loop Links Hypoxiaand Mitochondrial Signals in Pheochromocytomas , 2005 .